JP2003500010A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003500010A5 JP2003500010A5 JP2000604066A JP2000604066A JP2003500010A5 JP 2003500010 A5 JP2003500010 A5 JP 2003500010A5 JP 2000604066 A JP2000604066 A JP 2000604066A JP 2000604066 A JP2000604066 A JP 2000604066A JP 2003500010 A5 JP2003500010 A5 JP 2003500010A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acids
- mature
- seq
- polypeptide
- segment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001413 amino acids Chemical class 0.000 description 32
- 108090000765 processed proteins & peptides Proteins 0.000 description 28
- 229920001184 polypeptide Polymers 0.000 description 26
- 102000004196 processed proteins & peptides Human genes 0.000 description 26
- 241000288906 Primates Species 0.000 description 18
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 150000007523 nucleic acids Chemical class 0.000 description 15
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 14
- 102100038493 Cytokine receptor-like factor 1 Human genes 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 101710194728 Cytokine receptor-like factor 1 Proteins 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26790199A | 1999-03-11 | 1999-03-11 | |
| US09/267,901 | 1999-03-11 | ||
| PCT/US2000/006182 WO2000053631A1 (en) | 1999-03-11 | 2000-03-09 | Mammalian cytokines; related reagents and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003500010A JP2003500010A (ja) | 2003-01-07 |
| JP2003500010A5 true JP2003500010A5 (https=) | 2007-05-10 |
Family
ID=23020618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000604066A Pending JP2003500010A (ja) | 1999-03-11 | 2000-03-09 | 哺乳動物サイトカイン；関連試薬および方法 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1159299B1 (https=) |
| JP (1) | JP2003500010A (https=) |
| AR (1) | AR022890A1 (https=) |
| AT (1) | ATE420894T1 (https=) |
| AU (1) | AU3873200A (https=) |
| CA (1) | CA2366706A1 (https=) |
| DE (1) | DE60041393D1 (https=) |
| ES (1) | ES2319958T3 (https=) |
| WO (1) | WO2000053631A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2804435A1 (fr) * | 2000-01-27 | 2001-08-03 | Pf Medicament | COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFRalpha |
| US7045283B2 (en) * | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
| CN101052726A (zh) | 2003-05-09 | 2007-10-10 | 森托科尔公司 | IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途 |
| AR051444A1 (es) | 2004-09-24 | 2007-01-17 | Centocor Inc | Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos |
| SI2452694T1 (sl) | 2005-06-30 | 2019-05-31 | Janssen Biotech, Inc. | Protitelesa proti-IL-23, sestavki in postopki uporabe |
| PT1931710T (pt) | 2005-08-31 | 2017-03-28 | Merck Sharp & Dohme | Anticorpos anti-il-23 manipulados |
| HUE034269T2 (en) | 2005-12-29 | 2018-02-28 | Janssen Biotech Inc | Human anti-IL-23 antibodies, preparations, methods and applications |
| ES2708988T3 (es) | 2007-02-23 | 2019-04-12 | Merck Sharp & Dohme | Anticuerpos anti-IL-23p19 obtenidos por ingeniería genética |
| JP2010518858A (ja) | 2007-02-23 | 2010-06-03 | シェーリング コーポレイション | 操作された抗−ｉｌ−２３ｐ１９抗体 |
| CA2679400A1 (en) | 2007-02-28 | 2008-09-04 | Schering Corporation | Combination therapy for treatment of immune disorders |
| NZ579251A (en) | 2007-02-28 | 2012-06-29 | Schering Corp | Engineered anti-il-23r antibodies |
| ES2729603T3 (es) | 2012-06-27 | 2019-11-05 | Merck Sharp & Dohme | Anticuerpos IL-23 antihumanos cristalinos |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| MX2021004928A (es) | 2018-10-31 | 2021-06-08 | Merck Sharp & Dohme Llc | Cristales de anticuerpo anti-pd-1 humano y metodos de uso de los mismos. |
| EP3876990A4 (en) | 2018-11-07 | 2023-09-06 | Merck Sharp & Dohme LLC | CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES |
| IL283192B2 (en) | 2018-11-20 | 2025-10-01 | Janssen Biotech Inc | A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody |
| JP7805788B2 (ja) | 2019-05-23 | 2026-01-26 | ヤンセン バイオテツク，インコーポレーテツド | Ｉｌ－２３及びｔｎｆアルファに対する抗体の併用療法による炎症性腸疾患の治療方法 |
| IL298389A (en) | 2020-05-21 | 2023-01-01 | Janssen Biotech Inc | Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
| US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| DE3382317D1 (de) | 1982-03-15 | 1991-07-25 | Schering Corp | Hybride dns, damit hergestellte bindungszusammensetzung und verfahren dafuer. |
| US4659678A (en) | 1982-09-29 | 1987-04-21 | Serono Diagnostics Limited | Immunoassay of antigens |
| NZ207394A (en) | 1983-03-08 | 1987-03-06 | Commw Serum Lab Commission | Detecting or determining sequence of amino acids |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4859609A (en) | 1986-04-30 | 1989-08-22 | Genentech, Inc. | Novel receptors for efficient determination of ligands and their antagonists or agonists |
| US5470952A (en) * | 1993-10-20 | 1995-11-28 | Regeneron Pharmaceuticals, Inc. | CNTF and IL-6 antagonists |
| EP0759466B1 (en) * | 1995-08-01 | 2005-12-28 | F. Hoffmann-La Roche Ag | Low binding affinity interleukin-12 beta receptors |
| AUPO224696A0 (en) * | 1996-09-11 | 1996-10-03 | Amrad Operations Pty. Limited | A novel haemopoietin receptor and genetic sequences encoding same |
| AU5733898A (en) * | 1997-01-16 | 1998-08-07 | Genetics Institute Inc. | Member of the hematopoietin receptor superfamily |
| DE69825580T2 (de) * | 1997-02-03 | 2005-09-29 | Amgen Inc., Thousand Oaks | Neurotrophischer faktor nnt-1 |
| US5741772A (en) * | 1997-02-03 | 1998-04-21 | Amgen Inc. | Neurotrophic factor NNT-1 |
| WO1998049307A1 (en) * | 1997-05-01 | 1998-11-05 | Zymogenetics, Inc. | Mammalian cytokine-like receptor |
| US6046035A (en) * | 1997-06-30 | 2000-04-04 | Human Genome Sciences, Inc. | Polynucleotides encoding a cardiotrophin-like cytokine |
| GB9721961D0 (en) * | 1997-10-16 | 1997-12-17 | Glaxo Group Ltd | Novel molecules |
| NZ527900A (en) * | 1997-12-03 | 2005-02-25 | Genentech Inc | PRO361 polypeptides and nucleic acids with homology to mucin and chitinase |
| AU2454399A (en) * | 1998-01-09 | 1999-07-26 | Immunex Corporation | H14 dna and polypeptides |
| WO1999040195A1 (en) * | 1998-02-06 | 1999-08-12 | Schering Corporation | Mammalian receptor proteins; related reagents and methods |
| PT1181366E (pt) * | 1999-06-01 | 2009-05-25 | Schering Corp | Proteínas receptoras de mamífero; reagentes e métodos relacionados |
| FR2804435A1 (fr) * | 2000-01-27 | 2001-08-03 | Pf Medicament | COMPLEXE ISOLE COMPRENANT UNE PROTEINE NNT-1 ET EN OUTRE AU MOINS UNE PROTEINE CLF-1 ET/OU UNE PROTEINE sCNTFRalpha |
-
2000
- 2000-03-09 DE DE60041393T patent/DE60041393D1/de not_active Expired - Lifetime
- 2000-03-09 JP JP2000604066A patent/JP2003500010A/ja active Pending
- 2000-03-09 AU AU38732/00A patent/AU3873200A/en not_active Abandoned
- 2000-03-09 AR ARP000101059A patent/AR022890A1/es unknown
- 2000-03-09 ES ES00917821T patent/ES2319958T3/es not_active Expired - Lifetime
- 2000-03-09 AT AT00917821T patent/ATE420894T1/de not_active IP Right Cessation
- 2000-03-09 CA CA002366706A patent/CA2366706A1/en not_active Abandoned
- 2000-03-09 EP EP00917821A patent/EP1159299B1/en not_active Expired - Lifetime
- 2000-03-09 EP EP08103087A patent/EP1942114A3/en not_active Withdrawn
- 2000-03-09 WO PCT/US2000/006182 patent/WO2000053631A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003500010A5 (https=) | ||
| Yamasaki et al. | Identification of four nuclear transport signal-binding proteins that interact with diverse transport signals | |
| JP2004509617A5 (https=) | ||
| CN112062839A (zh) | 一种基于新型冠状病毒s蛋白s1亚基的纳米抗体及其应用 | |
| JP2003534013A5 (https=) | ||
| JPH02500329A (ja) | ターゲット化多機能蛋白質 | |
| KR900700606A (ko) | Ig-cd4융합 단백질을 코드화하는 클론된 유전자 및 그의 이용 | |
| JP2002508933A (ja) | 二官能分子 | |
| CN113698475B (zh) | 抗猪δ冠状病毒N蛋白的单克隆抗体和猪δ冠状病毒胶体金快速检测试纸条 | |
| CA2240409A1 (en) | Mammalian cx3c chemokine genes | |
| CN109293739B (zh) | 一种a3超家族通用肿瘤抗原多肽及其应用 | |
| Ståhl et al. | Engineered bacterial receptors in immunology | |
| EP0646173A1 (en) | Reagent for agglutination assays | |
| CN116284424B (zh) | 抗鼠抗体可结晶段的纳米抗体及其应用 | |
| CN116813765B (zh) | Rab8蛋白的特异性抗体及其制备方法与应用 | |
| CN106928355B (zh) | 一种CD105纳米抗体Nb184 | |
| CN110958886A (zh) | 恶性疟原虫和间日疟原虫疫苗 | |
| GB2282379A (en) | Conjugates of epitopes of HIV with a protein complex from Neisseria | |
| CN120518757B (zh) | 一种聚乙二醇化多价抗西尼罗病毒单链抗体 | |
| CN119978135B (zh) | Sumo标签蛋白的特异性抗体及其制备方法与应用 | |
| CN116640209B (zh) | Rab11蛋白的特异性抗体及其制备方法与应用 | |
| CN102276700A (zh) | 一种猪戊型肝炎病毒抗原表位及它的应用 | |
| CN106928359B (zh) | 一种CD105纳米抗体Nb59 | |
| JP2002510712A5 (https=) | ||
| WO1998036076A1 (en) | Modified treponema pallidum-derived antigen protein |